Business
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival AdvantageSALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-regimen, post hoc analysis of long-term survival in
About this update from Clene Inc.
[{"type":"image","alt":"Clene Inc.","displaySize":"","headline":null,"caption":"Clene Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/6ecbc5bc1ea840a1a7b45cd42deb4188"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dqllcqG43QFquU0vfLNVhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6ecbc5bc1ea840a1a7b45cd42deb4188","width":300,"height":72}},"lazy":false},{"type":"text","content":"New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage","length":92,"tagName":"p"},{"type":"text","content":"SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-regimen, post hoc analysis of long-term survival in HEALEY ALS Platform Trial participants. The analyses further substantiate that treatment with CNM-Au8® 30 mg delivers a significant survival benefit for people living with ALS.","length":584,"tagName":"p"},{"type":"text","content":"New Survival AnalysesThe analyses compared survival in participants who received CNM-Au8 30 mg (Regimen C) to those of Regimen A in the HEALEY ALS Platform Trial. Regimen A provided a large concurrent control group vs. CNM-Au8 treatment using the same randomization criteria established within the HEALEY master protocol. Long-term survival status, determined through public records and site reporting, was evaluated over a follow-up period of up to 48 months. 78% of participants across both groups received standard ALS background therapy (riluzole, edaravone, or both) at baseline.","length":585,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Overall Survival Improvement (All-Cause Mortality) Across the Full Analysis Set:","length":80,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Median Survival: CNM-Au8 30 mg group (Regimen C, n=59) achieved 951 days versus 753 days in the Regimen A comparator group (n=162) – a gain of 198 days (6.5 months)","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"Rest...